Faron Pharmaceuticals Oy (AIM:FARN)
42.00
-2.00 (-4.55%)
May 6, 2026, 4:42 PM GMT
Faron Pharmaceuticals Oy Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
33
Market Cap
87.79M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| hVIVO | 49.66M |
| Bioventix | 12.54M |
| Scancell Holdings | 4.71M |
| SkinBioTherapeutics | 4.64M |
| 4basebio | 1.78M |
| Arecor Therapeutics | 1.71M |
| Ondine Biomedical | 1.18M |
| ImmuPharma | -69.96K |
Faron Pharmaceuticals Oy News
- 7 weeks ago - Faron Pharmaceuticals Oy Transcript: Investor update - Transcripts
- 2 months ago - Faron Pharmaceuticals Oy (FRA:4FR) Full Year 2025 Earnings Call Highlights: Clinical Successes ... - GuruFocus
- 2 months ago - Full Year 2025 Faron Pharmaceuticals Oy Earnings Call Transcript - GuruFocus
- 2 months ago - Faron Pharmaceuticals Oy Earnings Call Transcript: H2 2025 - Transcripts
- 3 months ago - Faron Pharmaceuticals Oy Transcript: Investor update - Transcripts
- 6 months ago - Faron Pharmaceuticals Oy Transcript: ESMO 2025 Conference - Transcripts
- 9 months ago - Faron Pharmaceuticals Oy Earnings Call Transcript: H1 2025 - Transcripts
- 10 months ago - Faron Pharmaceuticals To Earn Spotlight At IUIS 2025 With Its Bexmarilimab Data - IBTimes